+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Progressive Fibrosing Interstitial Lung Disease Market Insight, Epidemiology and Market Forecast - 2032

  • PDF Icon

    Report

  • 181 Pages
  • August 2022
  • Region: Global
  • DelveInsight
  • ID: 4911966
This ‘Progressive Fibrosing Interstitial Lung Disease (PF-ILD)- Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Fibrosing Interstitial Lung Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Progressive Fibrosing Interstitial Lung Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive Fibrosing Interstitial Lung Disease market size from 2019 to 2032. The Report also covers current Progressive Fibrosing Interstitial Lung Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Progressive Fibrosing Interstitial Lung Disease- Disease Understanding and Treatment Algorithm

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.

Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.

Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.

Progressive Fibrosing Interstitial Lung Disease Diagnosis

Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.

The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.

Progressive Fibrosing Interstitial Lung Disease Treatment

Treatment for Interstitial Lung Diseases varies depending on the type of Interstitial Lung Disease diagnosed and the severity. Lung damage from Interstitial Lung Diseases is often irreversible and progressive, so treatment normally centers on relieving symptoms, improving quality of life and slowing the disease's progression. Medications, such as corticosteroids, can be used to decrease inflammation in the lungs.

Nintedanib (Ofev) is the only approved drug in the Progressive Fibrosing Interstitial Lung Disease treatment landscape. Along with Ofev the current market is mainly attributed to corticosteroids and immunosuppressants for treatment. Novel uses of antifibrotic therapies are emerging due to a paucity of evidence-based treatments for multiple Interstitial Lung Disease subtypes. The market is anticipates launch of several emerging therapies in the Progressive Fibrosing Interstitial Lung Disease treatment domain in the forecast period.

Progressive Fibrosing Interstitial Lung Disease Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

  • In the assessment done by the publisher, the estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in the 7MM were 322,197 cases in 2021.
  • The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
  • Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
  • Japan had 31,542 total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease for in 2021, accounting for approximately 10% in the 7MM.

Progressive Fibrosing Interstitial Lung Disease Epidemiology

The epidemiology segment also provides the Progressive Fibrosing Interstitial Lung Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Progressive Fibrosing Interstitial Lung Disease Drug Chapters

The drug chapter segment of the Progressive Fibrosing Interstitial Lung Disease report encloses the detailed analysis of Progressive Fibrosing Interstitial Lung Disease drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Progressive Fibrosing Interstitial Lung Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Progressive Fibrosing Interstitial Lung Disease Emerging Drugs

BI 1015550: Boehringer Ingelheim

BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects being developed by Boehringer Ingelheim. It has the potential to address both pulmonary fibrosis - an irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with Progressive Fibrosing Interstitial Lung Disease (ILDs). BI 1015550 represents the first molecule in the class of PDE4B inhibitors that is being studied for IPF and other progressive fibrosing ILDs. Breakthrough Therapy Designation was granted to BI 1015550 in February 2022 for the treatment of idiopathic pulmonary fibrosis (IPF) by the US Food and Drug Administration (FDA).

Pamrevlumab: FibroGen

FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.

As per the latest reports by FibroGen, topline data from the ZEPHYRUS-1 Phase III study of pamrevlumab in IPF is expected in mid-2023. Pamrevlumab has been granted Orphan Drug designation and Fast Track designation status in July 2012 and September 2018 respectively by the US FDA for the treatment of IPF.

Progressive Fibrosing Interstitial Lung Disease Market Outlook

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.

ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PF-ILDs. These unmet treatment gaps accentuates the launch of emerging therapies.

In the upcoming treatment landscape, there are plethora of companies investigating agents for use in the PF-ILD and IPF specific PF-ILD which includes Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd., Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB. There are many more pharma companies which are conducting clinical trials for therapies of PF-ILD and IPF specific PF-ILD.

Key Findings

  • The therapeutic market size of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM was USD 4,205 million in 2021.
  • The United States accounts for the highest market size of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) approximately 73% of the total market size in 7MM in 2021, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain),and Japan.
  • Among the EU5 countries, Germany had the highest market size with USD 228 million in 2021, while Spain had the lowest market size of Progressive Fibrosing Interstitial Lung Disease with USD 141 million in 2021.
  • The market size for Progressive Fibrosing Interstitial Lung Disease in Japan was estimated to be USD 222 Million in 2021, which accounts for 5% of the total 7MM market.
  • With the expected launch of upcoming therapies, such as BI 1015550, Pamrevlumab, and others the total market size of Progressive Fibrosing Interstitial Lung Disease (IPF and Non-IPF PF-ILD) is expected to show change in the upcoming years.

The United States Market Outlook

This section provides the total Progressive Fibrosing Interstitial Lung Disease market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Progressive Fibrosing Interstitial Lung Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Progressive Fibrosing Interstitial Lung Disease market size and market size by therapies in Japan are provided.

Progressive Fibrosing Interstitial Lung Disease Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Fibrosing Interstitial Lung Disease or expected to get launched in the market during the study period 2019-2032. The analysis covers Progressive Fibrosing Interstitial Lung Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Progressive Fibrosing Interstitial Lung Disease Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Progressive Fibrosing Interstitial Lung Disease emerging therapies.

Reimbursement Scenario in Progressive fibrosing interstitial lung diseases

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Progressive Fibrosing Interstitial Lung Disease market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Reports

  • The report covers the descriptive overview of Progressive fibrosing interstitial lung diseases, explaining its signs and symptoms, causes, classification, and currently available therapies.
  • Comprehensive insight has been provided into the Progressive Fibrosing Interstitial Lung Disease epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Progressive Fibrosing Interstitial Lung Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Progressive Fibrosing Interstitial Lung Disease market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Progressive Fibrosing Interstitial Lung Disease market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Progressive Fibrosing Interstitial Lung Disease market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Progressive Fibrosing Interstitial Lung Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
  • Major players are involved in developing therapies for Progressive fibrosing Interstitial lung diseases. The launch of emerging therapies will significantly impact the Progressive Fibrosing Interstitial Lung Disease market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Progressive Fibrosing Interstitial Lung Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Progressive Fibrosing Interstitial Lung Disease Pipeline Analysis
  • Progressive Fibrosing Interstitial Lung Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Progressive Fibrosing Interstitial Lung Disease Report Key Strengths

  • 11-Years Forecast
  • 7MM Coverage
  • Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Progressive Fibrosing Interstitial Lung Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions Answered

Market Insights:

  • What was the Progressive Fibrosing Interstitial Lung Disease market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Progressive Fibrosing Interstitial Lung Disease total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Progressive Fibrosing Interstitial Lung Disease market size during the forecast period (2022-2032)?
  • At what CAGR, the Progressive Fibrosing Interstitial Lung Disease market is expected to grow at the 7MM level during the forecast period (2022-2032)?
  • What would be the Progressive Fibrosing Interstitial Lung Disease market outlook across the 7MM during the forecast period (2022-2032)?
  • What would be the Progressive Fibrosing Interstitial Lung Disease market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Progressive Fibrosing Interstitial Lung Disease?
  • What is the historical Progressive Fibrosing Interstitial Lung Disease patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of Progressive Fibrosing Interstitial Lung Disease at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Progressive Fibrosing Interstitial Lung Disease?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Progressive Fibrosing Interstitial Lung Disease during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Progressive Fibrosing Interstitial Lung Disease along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Progressive Fibrosing Interstitial Lung Disease in the US, Europe, And Japan?
  • What are the Progressive Fibrosing Interstitial Lung Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Progressive Fibrosing Interstitial Lung Disease?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Progressive Fibrosing Interstitial Lung Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Progressive Fibrosing Interstitial Lung Disease therapies?
  • What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Progressive Fibrosing Interstitial Lung Disease and their status?
  • What are the key designations that have been granted for the emerging therapies for Progressive Fibrosing Interstitial Lung Disease?
  • What are the 7MM historical and forecasted market of Progressive Fibrosing Interstitial Lung Disease?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Progressive Fibrosing Interstitial Lung Disease.
  • To understand the future market competition in the Progressive Fibrosing Interstitial Lung Disease market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Progressive Fibrosing Interstitial Lung Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Progressive Fibrosing Interstitial Lung Disease market.
  • To understand the future market competition in the Progressive Fibrosing Interstitial Lung Disease market.
This product will be delivered within 1 business day.

Table of Contents

1. Key Insights2. Report Introduction
3. Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Market Overview at a Glance
3.1. Market Share (%) Distribution of PF-ILD by Therapies in 2019
3.2. Market Share (%) Distribution of PF-ILD by Therapies in 2032
4. Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market: Future Perspective5. Executive Summary of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)6. Key Events
7. Disease Background and Overview: Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
7.1. Introduction
7.2. Types of ILDs progressing into PF-ILD
7.2.1. IPF
7.2.2. Chronic hypersensitivity pneumonitis (HP)
7.2.3. Idiopathic nonspecific interstitial pneumonia (INSIP)
7.2.4. Unclassifiable idiopathic interstitial pneumonia (unclassifiable IIPs)
7.2.5. Autoimmune interstitial lung diseases (CTD-ILDs)
7.2.6. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
7.2.7. SSc-ILD
7.2.8. Connective tissue disease less commonly associated with PF-ILD
7.2.9. Chronic sarcoidosis
7.2.10. Exposure-related ILDs
7.3. Pathogenesis of PF-ILD
7.4. Predictors of Disease Progression
7.5. Diagnosis of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
7.6. Diagnostic Algorithm of PF-ILD
7.7. Treatment
7.7.1. Treatment Algorithm
7.7.2. Treatment Guidelines
7.7.3. ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of IPF
7.7.4. EULAR recommendations for the treatment of SSc-ILD
7.7.5. German Guideline for IPF-ILD
7.7.6. France Practical Guidelines for the Diagnosis and Management of IPF-ILD
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
8.3.1. United States
8.3.2. EU5 Countries
8.3.3. Japan
8.4. Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease in the 7MM
8.5. Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease in the 7MM
8.6. The United States
8.6.1. Total Prevalent Cases of ILD in the United States
8.6.2. Total Diagnosed Prevalent Cases of ILD in the United States
8.6.3. Type-specific Diagnosed Prevalent Cases of ILD in the United States
8.6.4. Total Diagnosed Prevalent cases of PF-ILD in the United States
8.7. Major Five European Countries
8.7.1. Total Prevalent Cases of ILD in the EU5
8.7.2. Total Diagnosed Prevalent Cases of ILD in the EU5
8.7.3. Type-specific Diagnosed Prevalent Cases of ILD in the EU5
8.7.4. Total Diagnosed Prevalent cases of PF-ILD in the EU-5
8.8. Japan
8.8.1. Total Prevalent Cases of ILD in Japan
8.8.2. Total Diagnosed Prevalent Cases of ILD in Japan
8.8.3. Type-specific Diagnosed Prevalent Cases of ILD in Japan
8.8.4. Total Diagnosed Prevalent cases of PF-ILD in Japan
9. Patient Journey
10. Marketed Therapies
10.1. Ofev (Nintedanib): Boehringer Ingelheim Pharmaceuticals, Inc.
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Other Development Activities
10.1.4. Clinical Development
10.1.5. Clinical Trial Information
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Esbriet (Pirfenidone): Hoffmann-La Roche Ltd
10.2.1. Product Description
10.2.2. Other Development Activities
10.2.3. Clinical Development
10.2.4. Clinical Trial Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
11. Emerging Drugs
11.1. Key Competitors
11.2. BI 1015550: Boehringer Ingelheim
11.2.1. Product Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trial Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.2.7. Analyst's Views
11.3. BMS-986278: Bristol-Myers Squibb
11.3.1. Product Description
11.3.2. Clinical Development
11.3.3. Clinical Trial Information
11.3.4. Product Profile
11.3.5. Analyst's View
11.4. Pamrevlumab: FibroGen
11.4.1. Product Description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.4.7. Analysts' Views
11.5. PRM-151 (RG6354): Hoffmann-La Roche Ltd
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.5.7. Analysts' Views
11.6. PLN-74809: Pliant Therapeutics, Inc.
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.6.7. Analysts' Views
11.7. Tyvaso (inhaled treprostinil): United Therapeutics
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.7.7. Analysts' Views
11.8. C21 (VP01): Vicore Pharma AB
11.8.1. Product Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.4. Clinical Trials Information
11.8.5. Safety and Efficacy
11.8.6. Product Profile
11.8.7. Analysts' Views
12. Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Seven Major Market Analysis
12.1. Key Findings
12.2. Methodology of PF-ILD Market
12.3. Market Outlook
12.4. Potential of Emerging Therapies
12.5. Key Market Forecast Assumptions
12.6. Market Size of PF-ILD in the 7MM
12.7. Market Size of PF-ILD by Therapies in the 7MM
12.8. Market Size of PF-ILD in the United States
12.8.1. Total Market Size of PF-ILD
12.8.2. Market Size of PF-ILD by Therapies
12.9. Market Size of PF-ILD in the EU5
12.9.1. Total Market Size of PF-ILD
12.9.2. Market Size of PF-ILD by Therapies
12.10. Market Size of PF-ILD in Japan
12.10.1. Total Market Size of PF-ILD
12.10.2. Market Size of PF-ILD by Therapies
13. Key Opinion Leaders' Views14. Market Drivers15. Market Barriers16. SWOT Analysis17. Unmet Needs18. Reimbursement and Market Access
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. Publisher Capabilities21. Disclaimer22. About the Publisher
List of Tables
Table 1: Summary of PF-ILD Market and Epidemiology (2019-2032)
Table 2: Key Events
Table 3: Total Diagnosed Prevalent cases of PF-ILD in the 7MM (2019-2032)
Table 4: Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019-2032)
Table 5: Total Prevalent Cases of ILD in the US (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Table 7: Type-specific Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Table 8: Total Diagnosed Prevalent Cases of PF-ILD in the US (2019-2032)
Table 9: Total Prevalent Cases of ILD in the EU5 (2019-2032)
Table 10: Total Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Table 11: Type-specific Diagnosed Prevalent Cases of ILD in Germany (2019-2032)
Table 12: Type-specific Diagnosed Prevalent Cases of ILD in France (2019-2032)
Table 13: Type-specific Diagnosed Prevalent Cases of ILD in Italy (2019-2032)
Table 14: Type-specific Diagnosed Prevalent Cases of ILD in Spain (2019-2032)
Table 15: Type-specific Diagnosed Prevalent Cases of ILD in the UK (2019-2032)
Table 16: Type-specific Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Table 17: Total Diagnosed Prevalent Cases of PF-ILD in the EU5 (2019-2032)
Table 18: Total Prevalent Cases of ILD in Japan (2019-2032)
Table 19: Total Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Table 20: Type-specific Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Table 21: Total Diagnosed Prevalent Cases of PF-ILD in Japan (2019-2032)
Table 22: Ofev (Nintedanib), Clinical Trial Description, 2022
Table 23: Esbriet (Pirfenidone), Clinical Trial Description, 2022
Table 24: Comparison of Emerging Drugs for PF-ILD
Table 25: BI 1015550, Clinical Trial Description, 2022
Table 26: BMS-986278, Clinical Trial Description, 2022
Table 27: Pamrevlumab, Clinical Trial Description, 2022
Table 28: PRM-151 (RG6354), Clinical Trial Description, 2022
Table 29: PLN-74809, Clinical Trial Description, 2022
Table 30: Tyvaso, Clinical Trial Description, 2022
Table 31: C21, Clinical Trial Description, 2022
Table 32: Key Market Forecast Assumptions for BI 1015550
Table 33: Key Market Forecast Assumptions for Pamrevlumab
Table 34: Key Market Forecast Assumptions for PRM-151 (RG6354)
Table 35: Key Market Forecast Assumptions for Tyvaso (treprostinil)
Table 36: Key Market Forecast Assumptions for PLN-74809
Table 37: Key Market Forecast Assumptions for VP01 (C21)
Table 38: Market Size of PF-ILD in the 7MM in USD Million (2019-2032)
Table 39: Market Size of PF-ILD by Therapies in the 7MM in USD Million (2019-2032)
Table 40: The United States Market Size of PF-ILD in USD Million (2019-2032)
Table 41: Market Size of PF-ILD by Therapies in the US in USD Million (2019-2032)
Table 42: The EU5 Market Size of PF-ILD in USD Million (2019-2032)
Table 43: Market Size of PF-ILD by Therapies in Germany in USD Million (2019-2032)
Table 44: Market Size of PF-ILD by Therapies in France in USD Million (2019-2032)
Table 45: Market Size of PF-ILD by Therapies in Italy in USD Million (2019-2032)
Table 46: Market Size of PF-ILD by Therapies in Spain in USD Million (2019-2032)
Table 47: Market Size of PF-ILD by Therapies in the UK in USD Million (2019-2032)
Table 48: Market Size of PF-ILD by Therapies in the EU5 in USD Million (2019-2032)
Table 49: Market Size of PF-ILD in Japan, in USD Million (2019-2032)
Table 50: Market Size of PF-ILD by Therapies in Japan in USD Million (2019-2032)
List of Figures
Figure 1: ILDs with Overlapping Area Shows the Probability of Having a Progressive-Fibrosing Phenotype
Figure 2: Known and Unknowns of PF-ILDs
Figure 3: Types of ILD Most Likely to Have a Progressive-fibrosing Phenotype
Figure 4: Fibrosis of the Alveolus Wall
Figure 5: Types of CTD-ILD
Figure 6: Concepts in the Pathogenesis of RA-ILD
Figure 7: Mechanisms in the Pathogenesis and Progression of Fibrosing Interstitial Lung Diseases
Figure 8: Diagnosis of ILDs that may present a Progressive Phenotype
Figure 9: Therapeutic Algorithm of PF-ILD
Figure 10: Total Diagnosed Prevalent Cases of PF-ILD in the 7MM (2019-2032)
Figure 11: Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019-2032)
Figure 12: Total Prevalent Cases of ILD in the US (2019-2032)
Figure 13: Total Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Figure 14: Type-specific Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Figure 15: Total Diagnosed Prevalent Cases of PF-ILD in the US (2019-2032)
Figure 16: Total Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 17: Total Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 18: Type-specific Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 19: Total Diagnosed Prevalent Cases of PF-ILD in the EU5 (2019-2032)
Figure 20: Total Prevalent Cases of ILD in Japan (2019-2032)
Figure 21: Total Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Figure 22: Type-specific Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Figure 23: Total Diagnosed Prevalent Cases of PF-ILD in Japan (2019-2032)
Figure 24: Patient Journey
Figure 25: Possible Potential of Emerging Therapies
Figure 26: Market Size of PF-ILD in the 7MM, in USD Million (2019-2032)
Figure 27: Market Size of PF-ILD by Therapies in the 7MM in USD Million (2019-2032)
Figure 28: Market Size of PF-ILD in the United States, USD Million (2019-2032)
Figure 29: Market Size of PF-ILD by Therapies in the United States, in USD Million (2019-2032)
Figure 30: Market Size of PF-ILD in the EU5, USD Million (2019-2032)
Figure 31: Market Size of PF-ILD by Therapies, in the EU5, in USD Million (2019-2032)
Figure 32: Market Size of PF-ILD in Japan, USD Million (2019-2032)
Figure 33: Market Size of PF-ILD by Therapies in Japan, in USD Million (2019-2032)
Figure 34: Market Drivers
Figure 35: Market Barriers
Figure 36: SWOT Analysis
Figure 37: Unmet Needs
Figure 38: European Pharmaceutical Markets

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • FibroGen
  • Hoffmann-La Roche Ltd
  • Pliant Therapeutics, Inc.
  • United Therapeutics
  • Vicore Pharma AB